Physician profile
Thusha N Nathan
NPI 1295718211
$1,864.09
in general payments reported to CMS, 2019-2025
15 companies · $388 in 2025
The $388 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $238 · 2022: $535 · 2023: $507 · 2024: $196 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,090.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $957.33 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $190.99 | 2022-2025 | Stelara, Tremfya |
| Aimmune Therapeutics, INC. | $140.89 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $120.28 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $114.81 | 2021-2024 | Dificid |
| Gilead Sciences, INC. | $110.53 | 2025 | |
| Pfizer INC. | $56.88 | 2023 | |
| Genzyme Corporation | $49.47 | 2023 | |
| Braintree Laboratories, INC. | $25.26 | 2022-2023 | Suflave, Sutab |
| Janssen Biotech, INC. | $21.13 | 2025 | Tremfya |
| Micro-Tech Endoscopy USA, INC. | $19.32 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.03 | 2025 | Entyvio |
| Lilly USA, LLC | $15.42 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $13.04 | 2021 | |
| Phathom Pharmaceuticals, INC. | $12.71 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thusha Nathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.